BACKGROUND: Inflammatory bowel disease (IBD) is characterised by infiltration of inflamed mucosal regions with CD4(+) T lymphocytes and other mononuclear cells. Interleukin (IL)-16 exerts a strong chemoattractant activity on CD4(+) cells. Moreover, IL-16 activates expression and production of proinflammatory cytokines such as IL-1beta, IL-6, IL-15, and tumour necrosis factor alpha (TNF-alpha) in human monocytes. AIM: To examine if IL-16 expression is increased in IBD patients compared with healthy controls. METHODS: Twenty one patients with IBD (10 with ulcerative colitis (UC), 11 with Crohn's disease (CD)), seven disease specificity controls (DSC), and seven healthy controls were studied. Biopsies were taken during colonoscopies and IL-16 mRNA as well as protein expression were investigated by reverse transcriptase-polymerase chain reaction, ELISA, western blot, and immunohistochemistry. RESULTS: IL-16 mRNA and protein expression in the colonic mucosa of IBD patients were increased twofold compared with healthy controls, DSC, or IBD patients under steroid treatment. Most of the detected IL-16 protein was in its bioactive 17 kDa form and was predominantly expressed in eosinophils. Increased IL-16 expression in UC patients appeared to be mainly restricted to the inflamed regions of the colonic mucosa. Levels of caspase 3, which processes the 68 kDa IL-16 precursor molecule into the biological active 17 kDa form, were not increased. CONCLUSIONS: Our results provide evidence that IL-16 expression is significantly increased in the inflamed colonic mucosa of IBD patients but not in control individuals, DSC, or patients under steroid treatment. Therefore, upregulation of IL-16 expression seems to be specific for chronic intestinal inflammation and could lead to increased secretion of other proinflammatory cytokines in IBD.
BACKGROUND:Inflammatory bowel disease (IBD) is characterised by infiltration of inflamed mucosal regions with CD4(+) T lymphocytes and other mononuclear cells. Interleukin (IL)-16 exerts a strong chemoattractant activity on CD4(+) cells. Moreover, IL-16 activates expression and production of proinflammatory cytokines such as IL-1beta, IL-6, IL-15, and tumour necrosis factor alpha (TNF-alpha) in human monocytes. AIM: To examine if IL-16 expression is increased in IBDpatients compared with healthy controls. METHODS: Twenty one patients with IBD (10 with ulcerative colitis (UC), 11 with Crohn's disease (CD)), seven disease specificity controls (DSC), and seven healthy controls were studied. Biopsies were taken during colonoscopies and IL-16 mRNA as well as protein expression were investigated by reverse transcriptase-polymerase chain reaction, ELISA, western blot, and immunohistochemistry. RESULTS:IL-16 mRNA and protein expression in the colonic mucosa of IBDpatients were increased twofold compared with healthy controls, DSC, or IBDpatients under steroid treatment. Most of the detected IL-16 protein was in its bioactive 17 kDa form and was predominantly expressed in eosinophils. Increased IL-16 expression in UC patients appeared to be mainly restricted to the inflamed regions of the colonic mucosa. Levels of caspase 3, which processes the 68 kDa IL-16 precursor molecule into the biological active 17 kDa form, were not increased. CONCLUSIONS: Our results provide evidence that IL-16 expression is significantly increased in the inflamed colonic mucosa of IBDpatients but not in control individuals, DSC, or patients under steroid treatment. Therefore, upregulation of IL-16 expression seems to be specific for chronic intestinal inflammation and could lead to increased secretion of other proinflammatory cytokines in IBD.
Authors: K G Lim; H C Wan; P T Bozza; M B Resnick; D T Wong; W W Cruikshank; H Kornfeld; D M Center; P F Weller Journal: J Immunol Date: 1996-04-01 Impact factor: 5.422
Authors: K Kusugami; A Fukatsu; M Tanimoto; M Shinoda; J Haruta; A Kuroiwa; K Ina; K Kanayama; T Ando; T Matsuura Journal: Dig Dis Sci Date: 1995-05 Impact factor: 3.199
Authors: W W Cruikshank; D M Center; N Nisar; M Wu; B Natke; A C Theodore; H Kornfeld Journal: Proc Natl Acad Sci U S A Date: 1994-05-24 Impact factor: 11.205
Authors: G Docena; L Rovedatti; L Kruidenier; A Fanning; N A B Leakey; C H Knowles; K Lee; F Shanahan; K Nally; P G McLean; A Di Sabatino; T T MacDonald Journal: Clin Exp Immunol Date: 2010-08-20 Impact factor: 4.330
Authors: Kan Yang; Natalia V Popova; Wan Cai Yang; Ioanna Lozonschi; Selam Tadesse; Scott Kent; Laura Bancroft; Ilze Matise; Robert T Cormier; Stefan J Scherer; Winfried Edelmann; Martin Lipkin; Leonard Augenlicht; Anna Velcich Journal: Cancer Res Date: 2008-09-15 Impact factor: 12.701
Authors: Hua Yu; Kevin Chen; Ying Sun; Mihaela Carter; Kevin W Garey; Tor C Savidge; Sridevi Devaraj; Mary Elizabeth Tessier; Erik C von Rosenvinge; Ciaran P Kelly; Marcela F Pasetti; Hanping Feng Journal: Clin Vaccine Immunol Date: 2017-08-04
Authors: Jennifer Racz; Gerta Mane; Michael Ford; Lindsay Schmidt; Jeffrey Myers; Theodore J Standiford; Kurt R Schumacher; Carlen Fifer; Mark W Russell; Kathleen A Stringer Journal: Ann Am Thorac Soc Date: 2013-04